Market News

Alder Biopharmaceuticals (ALDR) Position Upped by Senzar Asset Management Llc; Hmi Capital Stake In Autodesk (ADSK) Was Has Raised

Autodesk, Inc. (NASDAQ:ADSK) Logo

Mick Hellman increased its stake in Autodesk Inc (ADSK) by 32.08% based on its latest 2017Q4 regulatory filing with the SEC. Hmi Capital Llc bought 215,729 shares as the company’s stock rose 23.51% while stock markets declined. The hedge fund run by Mick Hellman held 888,220 shares of the technology company at the end of 2017Q4, valued at $93.11M, up from 672,491 at the end of the previous reported quarter. Hmi Capital Llc who had been investing in Autodesk Inc for a number of months, seems to be bullish on the $29.91 billion market cap company. The stock increased 0.43% or $0.59 during the last trading session, reaching $136.52. About 1.29 million shares traded. Autodesk, Inc. (NASDAQ:ADSK) has risen 50.18% since May 18, 2017 and is uptrending. It has outperformed by 38.63% the S&P500.

Senzar Asset Management Llc increased its stake in Alder Biopharmaceuticals Inc (ALDR) by 22.72% based on its latest 2017Q4 regulatory filing with the SEC. Senzar Asset Management Llc bought 145,700 shares as the company’s stock declined 1.29% with the market. The hedge fund held 786,870 shares of the health care company at the end of 2017Q4, valued at $9.01M, up from 641,170 at the end of the previous reported quarter. Senzar Asset Management Llc who had been investing in Alder Biopharmaceuticals Inc for a number of months, seems to be bullish on the $987.22M market cap company. The stock decreased 3.32% or $0.5 during the last trading session, reaching $14.55. About 873,879 shares traded. Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) has declined 46.26% since May 18, 2017 and is downtrending. It has underperformed by 57.81% the S&P500.

Since March 7, 2018, it had 0 buys, and 8 selling transactions for $6.09 million activity. Anagnost Andrew had sold 20,499 shares worth $2.57 million. $48,329 worth of Autodesk, Inc. (NASDAQ:ADSK) was sold by Di Fronzo Pascal W on Monday, April 2. Another trade for 20,458 shares valued at $2.53 million was sold by Blum Steven M. The insider BEVERIDGE CRAWFORD W sold $199,665.

Hmi Capital Llc, which manages about $266.04 million and $864.91M US Long portfolio, decreased its stake in Nice Ltd (NASDAQ:NICE) by 135,000 shares to 860,562 shares, valued at $79.09M in 2017Q4, according to the filing.

More notable recent Autodesk, Inc. (NASDAQ:ADSK) news were published by: Streetinsider.com which released: “JANA Shows New Stakes in Apple (AAPL), Boston Scientific (BSX), Dropbox (DBX), iQIYI (IQ) (more..) -13F” on May 15, 2018, also Streetinsider.com with their article: “Autodesk (ADSK) PT Raised to $150 at Deutsche Bank on 1Q Preview; ‘Expect ADSK to Exceed High End Revenue …” published on May 14, 2018, Streetinsider.com published: “Autodesk (ADSK) PT Raised to $160 at Morgan Stanley Amid Confidence in Billings Growth” on May 15, 2018. More interesting news about Autodesk, Inc. (NASDAQ:ADSK) were released by: Streetinsider.com and their article: “Tiger Global’s 13F Shows New Stake in Twitter (TWTR), Mercado (MELI), Increases Stake in Amazon (AMZN) (more…)” published on May 15, 2018 as well as Fool.com‘s news article titled: “General Motors and Autodesk Ally to Bring Driverless Electric Vehicle Future Closer” with publication date: May 07, 2018.

Among 27 analysts covering Autodesk Inc. (NASDAQ:ADSK), 18 have Buy rating, 3 Sell and 6 Hold. Therefore 67% are positive. Autodesk Inc. had 125 analyst reports since August 4, 2015 according to SRatingsIntel. The stock has “Buy” rating by Canaccord Genuity on Wednesday, November 29. Robert W. Baird maintained Autodesk, Inc. (NASDAQ:ADSK) on Thursday, August 24 with “Buy” rating. The rating was maintained by Credit Suisse with “Buy” on Wednesday, November 29. The stock of Autodesk, Inc. (NASDAQ:ADSK) earned “Overweight” rating by KeyBanc Capital Markets on Wednesday, March 7. Guggenheim maintained Autodesk, Inc. (NASDAQ:ADSK) rating on Wednesday, November 29. Guggenheim has “Buy” rating and $150.0 target. The stock of Autodesk, Inc. (NASDAQ:ADSK) earned “Outperform” rating by William Blair on Tuesday, August 4. Guggenheim maintained it with “Buy” rating and $150.0 target in Wednesday, March 7 report. The firm earned “Buy” rating on Wednesday, March 7 by Cowen & Co. The firm has “Buy” rating by RBC Capital Markets given on Sunday, September 3. RBC Capital Markets maintained the shares of ADSK in report on Friday, August 28 with “Outperform” rating.

Investors sentiment decreased to 1.08 in Q4 2017. Its down 0.34, from 1.42 in 2017Q3. It is negative, as 46 investors sold ADSK shares while 171 reduced holdings. 84 funds opened positions while 151 raised stakes. 204.78 million shares or 0.77% less from 206.38 million shares in 2017Q3 were reported. Antipodean Lc invested in 102,000 shares. Price T Rowe Inc Md reported 562,147 shares. 102,760 are owned by Bbva Compass State Bank. Glaxis Capital Mngmt Lc has 1.54% invested in Autodesk, Inc. (NASDAQ:ADSK) for 10,510 shares. Moreover, Salem Counselors Incorporated has 0.11% invested in Autodesk, Inc. (NASDAQ:ADSK) for 9,625 shares. Gofen Glossberg Limited Il, a Illinois-based fund reported 2,662 shares. Arrowstreet Partnership invested in 675,981 shares. Korea Investment accumulated 266,154 shares. Maplelane Limited Liability invested in 400,001 shares or 0.92% of the stock. Pictet Asset Mgmt Ltd reported 0.22% stake. California Employees Retirement owns 474,154 shares or 0.07% of their US portfolio. Loring Wolcott Coolidge Fiduciary Advsr Limited Liability Partnership Ma holds 20 shares. 303,505 were reported by State Teachers Retirement Sys. Proshare Advsr Ltd Liability Company holds 134,702 shares. Teachers Retirement Systems Of The State Of Kentucky stated it has 21,800 shares.

Among 17 analysts covering Alder Biopharmaceuticals (NASDAQ:ALDR), 14 have Buy rating, 1 Sell and 2 Hold. Therefore 82% are positive. Alder Biopharmaceuticals had 36 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) has “Buy” rating given on Thursday, June 29 by Aegis Capital. The company was maintained on Tuesday, January 30 by Canaccord Genuity. The firm earned “Buy” rating on Tuesday, January 2 by BMO Capital Markets. The stock has “Hold” rating by Credit Suisse on Thursday, August 24. Piper Jaffray maintained the shares of ALDR in report on Tuesday, June 27 with “Buy” rating. RBC Capital Markets maintained the stock with “Buy” rating in Monday, January 8 report. The firm earned “Buy” rating on Thursday, June 8 by Needham. The stock of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) has “Overweight” rating given on Tuesday, September 13 by JP Morgan. The stock has “Buy” rating by Jefferies on Wednesday, September 9. The stock has “Outperform” rating by BMO Capital Markets on Wednesday, August 9.

More notable recent Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) news were published by: Nasdaq.com which released: “Research Report Identifies Armstrong World Industries, Empire State Realty Trust, Alder BioPharmaceuticals, Cadence …” on May 17, 2018, also Benzinga.com with their article: “Goldman Sachs Neutral On Alder Biopharma As Launch Of Migraine Treatment Approaches” published on April 24, 2018, Globenewswire.com published: “Alder BioPharmaceuticals┬« Reports First Quarter 2018 Financial and Operating Results” on May 08, 2018. More interesting news about Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) were released by: Streetinsider.com and their article: “Alder BioPharma (ALDR) Presents 12-Month Data of Eptinezumab in PROMISE 1 Phase 3 Trial Showing Long-Term …” published on April 24, 2018 as well as Globenewswire.com‘s news article titled: “Alder BioPharmaceuticals┬« Appoints Jeremy Green to its Board of Directors” with publication date: April 26, 2018.

Senzar Asset Management Llc, which manages about $442.00M and $391.71 million US Long portfolio, decreased its stake in Allergan Plc (Prn) by 18,600 shares to 25,000 shares, valued at $14.66M in 2017Q4, according to the filing. It also reduced its holding in Allergan Plc by 11,200 shares in the quarter, leaving it with 48,900 shares, and cut its stake in Protagonist Therapeutics Inc.

Autodesk, Inc. (NASDAQ:ADSK) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *